BGM Group Ltd.
BGM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BGM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BGM
BGM Group Ltd. is a holding company engaged in the research, development, and production of licorice products, oxytetracycline, traditional Chinese medicine, heparin, sausage casings, and fertilizers, with a strategic focus on AI, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals [sec · filed 2026-07-21].
Key risk: Insufficient working capital
Market Cap
$131.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Sep 30, 2025.
BGM Group Ltd. is a holding company engaged in the research, development, and production of licorice products, oxytetracycline, traditional Chinese medicine, heparin, sausage casings, and fertilizers, with a strategic focus on AI, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals [sec · filed 2026-07-21].
- As of September 30, 2025, BGM had cash and cash equivalents of approximately $9.8M and total current assets of $51.5M against total current liabilities of $17.9M [sec · filed 2026-07-21].
- The company estimates it will need at least $50 million in the next 3 years to fund its business plans, including acquiring traditional Chinese medicine enterprises [sec · filed 2026-07-21].
- BGM's operations are conducted through a WFOE and a VIE structure, with the company noting it has limited sources of working capital and will need substantial additional financing [sec · filed 2026-07-21].
- The company's business spans multiple sectors: licorice products, oxytetracycline, TCMD, heparin, sausage casings, fertilizers, and emerging technology fields such as AI, intelligent robots, and cloud computing [sec · filed 2026-07-21].
What works
- BGM has a diversified product portfolio across pharmaceuticals, chemicals, and food products (licorice, oxytetracycline, heparin, sausage casings), which may provide multiple revenue streams [sec · filed 2026-07-21].
- The company is strategically expanding into high-growth technology areas including AI application, intelligent robots, algorithmic computing power, and cloud computing [sec · filed 2026-07-21].
What to weigh
- BGM has limited working capital and will need substantial additional financing; as of September 30, 2025, cash was only $9.8M against an estimated $50M funding need over three years [sec · filed 2026-07-21].
- The company's VIE structure exposes it to regulatory and corporate governance risks, and it cannot assure it can maintain all required licenses and permits [sec · filed 2026-07-21].
- BGM faces significant competition and evolving government policies that could adversely affect its business and financial performance [sec · filed 2026-07-21].
- The company has a history of operating losses and accumulated deficits, and there is no assurance it will generate sufficient revenues to sustain operations [sec · filed 2026-07-21].
From the filings
Quoted directly from source documents.
BGM needs at least $50 million in the next 3 years for business plans including acquiring TCM enterprises.
“We estimate that carrying out these business projects will require at least $50 million in the next 3 years.”
SEC filings · July 21, 2026
As of September 30, 2025, BGM had cash of approximately $9.8M.
“As of September 30, 2025, we had cash and cash equivalents of approximately $9,820,440”
SEC filings · July 21, 2026
BGM's business includes AI, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals.
“We also have a strategic focus on the technology fields of AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals.”
SEC filings · July 21, 2026
BGM has limited working capital and will need substantial additional financing.
“We and our affiliated entities have limited sources of working capital and will need substantial additional financing.”
SEC filings · July 21, 2026
Risks & what to watch (4)›
Key risks
- Insufficient working capital — Cash of $9.8M as of Sep 2025 is far below the estimated $50M needed over 3 years [sec · filed 2026-07-21].
- VIE structure regulatory risk — Operations depend on VIE structure; company cannot assure it can maintain all required permits [sec · filed 2026-07-21].
- Competition and policy risk — Intense competition and evolving government policies could materially affect business [sec · filed 2026-07-21].
- Dilution from future financing — Capital-raising transactions may cause substantial dilution to shareholders [sec · filed 2026-07-21].
What to watch
- Ability to raise additional capital to meet the estimated $50M funding requirement over the next three years [sec · filed 2026-07-21].
- Progress in the strategic expansion into AI, intelligent robots, algorithmic computing power, and cloud computing [sec · filed 2026-07-21].
- Regulatory developments affecting the VIE structure and the company's ability to maintain required licenses and permits [sec · filed 2026-07-21].
- Revenue generation from diversified product lines (licorice, oxytetracycline, heparin, etc.) and any new product candidates [sec · filed 2026-07-21].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run BGM Group Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BGM Group Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of May 20, 2026- % of float
- 0.0%
- Days to cover
- 0.2
- Shares short
- 45,306
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BGM short interestFrequently asked questions
What is the AI investment thesis for BGM Group Ltd.?
BGM Group Ltd. is a holding company engaged in the research, development, and production of licorice products, oxytetracycline, traditional Chinese medicine, heparin, sausage casings, and fertilizers, with a strategic focus on AI, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals [sec · filed 2026-07-21].
Who is the CEO of BGM Group Ltd.?
Ms. Huandi Zhao is the chief executive officer of BGM Group Ltd. (BGM).
Where is BGM Group Ltd. headquartered?
BGM Group Ltd. (BGM) is headquartered in Chengdu, China.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.